, a concern that has ramped up in the aftermath of pandemic-induced disruptions to global trade. The research project will in part probe the extent of foreign influence on U.S. drug supplies, including from China.
Quantifind Inc., a company that normally does risk screening for financial institutions, will do the work, looking into supply chains for the Cross-Border Threat Screening and Supply Chain Defense Center of Excellence, a government-backed research center connected with Texas A&M University.Our Morning Risk Report features insights and news on governance, risk and compliance.
The country of origin of a finished drug can be readily determined, but the materials that went into it—including so-called active pharmaceutical ingredientsor APIs—can be harder to trace. The new DHS-backed study will try to map out supply chains several layers deep, and potentially uncover previously hidden issues, Mr. Tuchman said.
Beyond APIs, China is the source of many key starting materials used to make drugs, said Rosemary Gibson, a senior adviser at the Hastings Center bioethics think-tank and author of the book “China Rx.” Food and Drug Administration figures presented to Congress in 2019 showed the number of Chinese facilities making APIs doubled from 2010 to 2019, though the FDA said then that the U.S. hosted the largest number of facilities.
Why spend the money? It's obvious China is using unnecessary yet intentional lockdowns to punish the west.
Weakness number 1, offshored production of medicines. I am not even a robot, BOOM !!